FibroGen (NASDAQ:FGEN) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

FGEN has been the topic of several other research reports. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th. StockNews.com assumed coverage on FibroGen in a research report on Thursday, February 13th. They issued a “hold” rating on the stock.

FibroGen Trading Up 37.4 %

NASDAQ FGEN opened at $0.77 on Thursday. The firm’s 50 day simple moving average is $0.52 and its 200 day simple moving average is $0.43. The firm has a market capitalization of $77.83 million, a price-to-earnings ratio of -0.63 and a beta of 0.75. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80.

Institutional Trading of FibroGen

A number of hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC acquired a new stake in shares of FibroGen during the 4th quarter valued at $27,000. Velan Capital Investment Management LP bought a new position in FibroGen in the fourth quarter valued at about $42,000. XTX Topco Ltd boosted its stake in shares of FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares in the last quarter. Franklin Street Advisors Inc. NC grew its holdings in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares during the last quarter. Finally, FMR LLC increased its stake in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 68,569 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.